Nonalcoholic steatohepatitis

1 paper1 finding

In silico1

Effects

1

Mortality

upin humans1

1 study

Nonalcoholic steatohepatitis increases mortality in humans (AAPC 0.82).
Humans
Global trends, health inequalities, and long-term projections concerning liver cancer mortality attributable to nonalcoholic steatohepatitis between 1990 and 2050
iLIVER22 Aug 2026

Trial sponsors

Gilead Sciences
Company3 trialsPhase 2640 people
Merck & Co.
Company2 trialsPhase 2526 people
Chemomab Therapeutics
Company2 trialsPhase 231 people
Eli Lilly and Company
Company1 trialPhase 2190 people
Intercept Pharmaceuticals
Company1 trialPhase 284 people
Lipocine
Company1 trialPhase 256 people
Oramed
Company1 trialPhase 27 people
VA Office of Research and Development
2 trialsPhase 4233 people

Funding

1 grant since 2002

National Institute of Diabetes and Digestive and Kidney DiseasesUS$250k

Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)
National Institute of Diabetes and Digestive and Kidney DiseasesDuke UniversityUS$250k2002–2027

Latest

1 in 12 months

ILIVER14 Sep

Global trends, health inequalities, and long-term projections concerning liver cancer mortality attributable to nonalcoholic steatohepatitis between 1990 and 2050

Computational studyLiver cancer

ENDO 2025 Abstract23 Oct

SAT-662 GLP-1 And Advanced NASH: Impact On Liver Fibrosis Regression

ReviewInterventions